{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:28:06Z","timestamp":1762475286246,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jdcr.2021.09.009","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:31:53Z","timestamp":1632270713000},"page":"18-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine"],"prefix":"10.1016","volume":"17","author":[{"given":"Jose W.","family":"Ricardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.jdcr.2021.09.009_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jdcr.2021.09.009_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2021.09.009_bib3","first-page":"e632","article-title":"Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine","volume":"35","author":"Krajewski","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2021.09.009_bib4","doi-asserted-by":"crossref","first-page":"258430","DOI":"10.1155\/2015\/258430","article-title":"Possible triggering effect of influenza vaccination on psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.jdcr.2021.09.009_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2340\/00015555-0496","article-title":"Psoriatic skin lesions induced by BCG vaccination","volume":"88","author":"Takayama","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdcr.2021.09.009_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jdcr.2021.05.026","article-title":"Telogen effluvium, Beau lines, and acral peeling associated with COVID-19 infection","volume":"13","author":"Deng","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"24","key":"10.1016\/j.jdcr.2021.09.009_bib7","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.2169\/internalmedicine.6112-20","article-title":"Beau's lines and leukonychia in a COVID-19 patient","volume":"59","author":"Ide","year":"2020","journal-title":"Intern Med"},{"key":"10.1016\/j.jdcr.2021.09.009_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.17448","article-title":"A review of nail findings associated with COVID-19 infection","author":"Hadeler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621006433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621006433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:23:20Z","timestamp":1762475000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621006433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":8,"alternative-id":["S2352512621006433"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.009","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}